알루미스 (ALMS) 주가

알루미스(ALMS)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $7.77 (-0.64%), 시가총액 $2.92B, 52주 범위 $2.80 ~ $29.98.

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc.

핵심 지표

• 현재가: $7.77 (-0.64%)
• 시가총액: $2.92B
• 52주 최저~최고: $2.80 ~ $29.98
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NAS

알루미스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.

알루미스 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 적극 매수 (4.7 / 5)

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 9.99
• 순이익률: 0.00%

자주 묻는 질문